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 1 
Investigation of physical activity using accelerometry in dogs receiving chemotherapy. 2 
 3 
Summary  4 
 5 
Objectives 6 
To perform a preliminary study to assess whether single-agent palliative or adjuvant 7 
chemotherapy has an impact on objectively measured physical activity (PA) in dogs.  8 
 9 
Methods 10 
Fifteen dogs with neoplasia (treatment group (TG)) wore ActiGraphTM accelerometers for 11 
five day periods; before, during and after receiving single-agent, adjuvant or palliative 12 
chemotherapy. Mean 5-day volume of PA and time spent in 3 different intensities of PA 13 
(sedentary, light-moderate and vigorous) before, during and after receiving chemotherapy 14 
were compared to a group of fifteen healthy dogs (control group (CG)). Results were also 15 
compared within the treatment group across time.  16 
  17 
 Results 18 
Prior to chemotherapy, TG dogs tended to be less active than CG dogs. Treatment group dogs 19 
were slightly more active at restaging than they were prior to treatment but had similar 20 
activity levels to CG dogs. Marked effects of chemotherapy on PA were not found. Physical 21 
activity was slightly lower in TG dogs during chemotherapy when compared to CG dogs but 22 
when PA of TG dogs was compared before and during chemotherapy, a slight increase in PA 23 
was seen. Additionally, little change in the mean 5-day volume of PA was seen between TG 24 
dogs on chemotherapy and at restaging. However, a mild decline in the time spent sedentary 25 
and increase in time spent in light-moderate activity was seen at restaging.  26 
 2 
 27 
Clinical Significance 28 
Single-agent, adjuvant or palliative chemotherapy, measured objectively had minimal impact 29 
upon PA or in dogs with neoplasia.  30 
 31 
Keywords 32 
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 34 
Introduction 35 
Veterinary chemotherapy is a growing field and patients are often either treated to ameliorate 36 
clinical signs (in the case of unresectable or disseminated disease, so called palliative intent 37 
treatment) or to prolong survival in those with micro-metastatic disease following surgery or 38 
radiation therapy (adjuvant chemotherapy). Traditionally, outcomes of veterinary 39 
chemotherapy studies have concentrated on drug tolerability, adverse events (primarily 40 
effects on the haemopoietic and gastrointestinal systems), tumour response and survival 41 
parameters (for example median survival times, disease free intervals or time to tumour 42 
progression) (Mellanby and others 2003, Ehrhart and others 2013). In both humans and 43 
animals it has been suggested that the measure of outcomes of cancer trials, particularly those 44 
investigating palliative and adjuvant chemotherapy protocols, should also include measures 45 
of patient quality of life (QOL) (Spitzer and others 1981, Gunnars and others 2001, Sprangers 46 
2002). Acceptable QOL during cancer treatment is important to both pet owners (Mellanby 47 
and others 2003) and veterinarians (Yeates and Main 2009). The risk of prolonging or 48 
inducing suffering, or of reducing QOL is often cited by owners as a reason for electing 49 
euthanasia rather than treatment (Slater and others 1996). Therefore, a better understanding of 50 
the effects of treatments on QOL would help with informed decision making. In patients 51 
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receiving palliative or adjuvant treatment, patient QOL is affected not only by the treatment 52 
itself but also by residual disease. The goals of treatment are thus to achieve a balance 53 
between an anti-tumour response and increased patient longevity whilst avoiding deleterious 54 
effects on patient QOL.  55 
 56 
Quality of life is multifactorial and includes a range of physical and behavioural parameters. 57 
It is difficult to define and the concept likely varies between different people (McMillan 58 
2000, Gunnars and others 2001). One symptom included in QOL questionnaires in people 59 
with cancer is fatigue (Aaronson and others 1983, the WHOQOL Group 1998, Carrison and 60 
Hamrin 1996). Fatigue, an extreme form of tiredness, is one of the most commonly reported 61 
side-effects of chemotherapy (Skerman and others 2012, Backman and others 2014). It is 62 
multifactorial and is thought to result in a reduction in physical activity (PA) (Vermaete and 63 
others 2014). Studies in humans using accelerometers to objectively measure PA have shown 64 
that it is reduced in patients on chemotherapy (Tan and others 2013, Vermaete and others 65 
2014).  66 
 67 
In veterinary medicine, assessment of QOL in oncology patients has been largely subjective, 68 
often using owner questionnaires either to ask them to quantify their pet’s QOL or to ask 69 
about specific determinants of QOL such as demeanor, appetite, pain and mobility (Fox and 70 
others 2000, Malik and others 2001, Mellanby and others 2003, Tzannes and others 2008, 71 
Bowles and others 2010, Lynch and others 2011, Iliopoulou and others 2013). It is not 72 
possible in veterinary studies to determine whether the patient feels fatigued and therefore PA 73 
levels have been subjectively assessed by asking questions about the patients’ mobility, 74 
tiredness, lethargy and play activity (Bowles and others 2010, Iliopoulou and others 2013, 75 
Rivera and others 2013). The inclusion of questions regarding PA confirms the importance of 76 
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its evaluation in QOL assessment but using this methodology; it is difficult to quantify 77 
changes in PA and the results may be biased by client preconceptions of chemotherapy. 78 
Comparison between clients is also difficult as the perception of PA likely varies between 79 
different people. In addition, questionnaires are often completed retrospectively, sometimes 80 
months after the administration of chemotherapy (Mellanby and others 2003, Tzannes and 81 
others 2008, Bowles and others 2010). The detection of diminished activity during cancer 82 
treatment may be even more relevant in veterinary patients, where the incapacitation that 83 
accompanies treatment in some people would simply not be acceptable in our patients. 84 
 85 
Using data collected from owners, reductions in PA have been reported in some dogs 86 
following treatment with single-agent carboplatin, doxorubicin, epirubicin and mitoxantrone, 87 
all of which are drugs used in palliative or adjuvant settings (Ogilvie and others 1991, Lucroy 88 
and others 1998, Bowles and others 2010, Marrington and others 2012). It however unknown 89 
to what extent reductions in PA actually occur in patients receiving these chemotherapy 90 
agents and objective measurements of PA in veterinary patients receiving chemotherapy has 91 
not been attempted. 92 
 93 
Accelerometers are motion sensors that provide real-time monitoring of the frequency, 94 
duration and intensity of PA in free-living individuals. They have been used extensively in 95 
adults and children, both with and without cancer, to objectively measure PA (Corder and 96 
others 2008, Reilly and others 2008, deVries and others 2009, Tan and others 2013, Vermaete 97 
and others 2014, Lowe and others 2014). Accelerometers have been validated for the 98 
measurement of habitual PA in dogs (Yam and others 2011). They have the advantage of 99 
giving a quantitative measure of PA whilst being portable, lightweight and non-invasive. 100 
 101 
 5 
The aims of this preliminary study were to objectively measure PA in dogs using 102 
accelerometers, before, during and after receiving palliative intent or adjuvant single-agent 103 
chemotherapy, and to compare PA in the chemotherapy treatment group to that of a control 104 
group of healthy dogs. In so doing, we hope to better understand the extent to which a 105 
reduction in PA truly occurs in these patients. 106 
 107 
Materials and Methods   108 
In this prospective study, all dogs presented to a veterinary teaching hospital from March 109 
2012 to October 2013 and suspected of having a malignant tumour were considered for 110 
inclusion.  Dogs eligible for the treatment group (TG) were subsequently excluded if 111 
histopathology was not consistent with malignant neoplasia, they did not receive single-agent 112 
chemotherapy, they were inconsistently treated with other drugs (including non-steroidal 113 
anti-inflammatory drugs, opioids and corticosteroids) or modalities (including radiotherapy) 114 
throughout their chemotherapy or they had significant co-morbidities that could 115 
independently affect activity levels (such as cardiac disease, osteoarthritis, endocrine or 116 
metabolic disorders). Co-morbidities were excluded on the basis of the history, physical 117 
examination and staging results. Any additional tests were performed on a case-by-case basis 118 
at the clinician’s discretion.  119 
 120 
The final TG therefore consisted of dogs that had malignant neoplasms, had undergone full 121 
staging (complete blood count (CBC), blood biochemistry panel, thoracic radiography or 122 
computed tomography and abdominal ultrasound examination) and received single-agent 123 
chemotherapy (carboplatin, doxorubicin, epirubicin or mitoxantrone). For each TG dog, a 124 
control dog matched as closely as possible for sex, age, weight, body condition score (BCS) 125 
and breed was included in a control group (CG). Control dogs were client-owned healthy 126 
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individuals that were taking part in a concurrent study (Morrison and others 2013a, Morrison 127 
and others 2013b, Morrison and others 2014).  128 
 129 
Chemotherapy was administered via the standard hospital protocol, in brief; CBCs were 130 
performed immediately prior to chemotherapy administration and treatments were delayed if 131 
neutrophil counts were <3 x 109 L-1.  Carboplatin was administered at 300 mg/m2 q3 weeks, 132 
doxorubicin and epirubicin at 30 mg/m2 q3 weeks and mitoxantrone at 5.5 mg/m2 q3 weeks 133 
for a total of four to six treatments. Chemotherapy was administered through an intravenous 134 
catheter in a saline infusion over 20 minutes.  Cases were discharged on the day of treatment. 135 
Supportive medications (for example anti-emetics) were administered according to standard 136 
protocols or when adverse events were experienced.  Dogs receiving analgesic drugs or 137 
nutraceutical joint supplements were only included if they remained on the same drug and 138 
dose throughout the study.  139 
 140 
Physical activity was measured using GT3-X and GT3-X+ accelerometers (ActiGraph™) 141 
attached to the dog’s collar, as previously described (figure 1) (Yam and others 2011). 142 
Accelerometers were placed for a minimum of 5 consecutive 24-hour periods. For the TG 143 
dogs, accelerometers were first placed at initial presentation or postoperatively. When placed 144 
postoperatively this had to be at least 7 days, and as long as possible, following surgery but 145 
no less than 5 days prior to chemotherapy administration. After this, accelerometers were 146 
removed by owners and returned by post for the data to be downloaded. All owners 147 
completed a diary detailing any problems associated with the accelerometer placement (e.g. 148 
collar removal or loss during the measurement period).  Accelerometers were again placed 149 
when patients returned for their first (C1), third (C3) and fifth (C5) doses of chemotherapy 150 
and were set to start recording from midnight on the day of chemotherapy administration. 151 
 7 
The final accelerometer was placed a minimum of 1 month after the final dose of 152 
chemotherapy when dogs returned for restaging.  Control group dogs had accelerometers 153 
placed on one occasion. 154 
 155 
 The accelerometer measured and recorded time-varying accelerations ranging in magnitude 156 
from approximately 0.05 to 2.5g (GT3-X) and +/- 6g (GT3-X+) in 3 axes. There is excellent 157 
agreement between these two models meaning that they can be used interchangeably within 158 
the same study (Robusto and Trost 2012). The accelerometer output was digitised by a 12-bit 159 
analog to digital converter at a rate of 30 times per second (30 Hz). Once digitised, the signal 160 
passed through a filter that band limited the accelerometer to the frequency range of 0.25 to 161 
2.5 Hz to eliminate any acceleration noise outside the normal activity frequency bandwidth. 162 
Each sample was summed over a 15 second time interval (epoch).  163 
 164 
Actilife v6.6.2 software (ActiGraph™) was used to download the data. This software also 165 
calculated the integrated output (Vector Magnitude) which is the magnitude of the resulting 166 
vector that forms when combining the sampled acceleration from all 3 axes (ActiGraphTM 167 
2013). The raw data files were imported to a Microsoft Office Excel 2007 (Microsoft) 168 
spreadsheet. Outputs were analysed from the integrated output and data was expressed in 169 
counts per minute (cpm) by summing the counts from 4 epochs. Figure 2 shows a graph of 170 
the PA (calculated from the integrated output) for a dog over a 24 hour period. 171 
 172 
The mean daily volume of PA per minute (cpm) and the mean 5-day volume of PA per 173 
minute (cpm) were calculated for each dog at each timepoint. The amount of time 174 
(minutes/day) spent in 3 different intensities of activity (sedentary, light-moderate and 175 
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vigorous) was calculated for each day and and a daily mean calculated for each 5 day period. 176 
The three levels of activity were defined as follows (from Yam and others 2011): 177 
1) Sedentary behaviour - no movement of the trunk, includes time spent sleeping 178 
2) Light to moderate intensity PA - slow to moderate translocation of the trunk, with the 179 
dog on a lead 180 
3) Vigorous intensity PA - rapid translocation of the trunk whilst running (usually 181 
outdoors) off a lead.   182 
Each minute was categorised as spent in sedentary behaviour, light-moderate intensity or 183 
vigorous intensity PA using cut points based on a “calibration” study derived from data 184 
obtained in a previous validation of the ActiGraph™ accelerometers (Yam and others 2011, 185 
Morrison and others 2013a).    186 
 187 
Data was also recorded on signalment, staging results, surgical treatment, tumour type, 188 
chemotherapy administered, concurrent medications, concurrent physiotherapy or 189 
hydrotherapy, adverse events, and outcome of TG dogs. 190 
 191 
Data were tested for normality using the Anderson-Darling test. As data was not normally 192 
distributed, median and interquartile ranges (IQR) were calculated. The median of the mean 193 
5-day volume of PA per minute and medians of the mean daily time (minutes/day) spent at 194 
each intensity of PA for the 5 day periods were calculated for the CG. To compare the PA of 195 
the treatment dogs and control dogs pre-treatment, after chemotherapy and after restaging, 196 
box and whisker plots of the mean 5-day volume of PA per minute were drawn. The medians 197 
of the mean daily time (minutes/day) spent at each intensity of PA for the 5 day periods were 198 
calculated for each time point for the treatment dogs and their paired control dogs. To 199 
examine the effect of chemotherapy on the TG dogs, the difference in the mean 5-day volume 200 
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of PA per minute and the difference in mean daily time (minutes/day) spent at each intensity 201 
of PA for each 5 day period at different time points was calculated for each dog. Results were 202 
then graphed or median differences were calculated. Dogs were only included if they had 203 
data available from both time points. Finally, to determine changes in TG dogs over the 5 204 
days following each chemotherapy dose, box and whisker plots of the mean daily volume of 205 
PA per minute were drawn and the median time spent each day at each intensity of PA were 206 
calculated. Analyses were carried out and graphs drawn using Minitab 16.1.1 (Minitab Inc.) 207 
and Microsoft Office Excel 2007 (Microsoft).  208 
 209 
Informed consent was given by all dog owners and the study was approved by the relevant 210 
Ethics and Welfare Committee. 211 
 212 
Results 213 
Twenty five dogs were recruited to the TG, however 2 dogs were ultimately diagnosed with 214 
non-neoplastic diseases, 4 dogs were not treated with chemotherapy and 2 dogs were 215 
intermittently treated with other drugs or radiotherapy. Of the remaining 17 dogs, 2 were 216 
excluded due to corrupt accelerometer data.  217 
 218 
The TG and CG dog descriptive characteristics are shown in Table 1. Matching for breed 219 
between the TG and CG dogs was not possible.  220 
 221 
All TG dogs had solid tumours; 3 anal sac adenocarcinomas, 2 malignant melanomas, 3 222 
appendicular osteosarcomas, 3 haemangiosarcomas, one splenic sarcoma, one soft tissue 223 
sarcoma, one mammary carcinoma and one nasal adenocarcinoma.  Fourteen dogs (93%) 224 
were staged to the local site only and one dog had local lymph node involvement. None of the 225 
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dogs had distant metastases at the time of diagnosis. Fourteen dogs had surgery to de-bulk 226 
gross disease before entering the study. The dog with a nasal tumour did not have surgery. Of 227 
these 14 dogs, 9 (60%) had accelerometers placed prior to chemotherapy and therefore had 228 
baseline data collected.  Eight of these had surgery and this included two limb amputations, 229 
one splenectomy, two anal sac resections for stage I anal sac adenocarcinoma, one debulking 230 
of a maxillary malignant melanoma, one enucleation due to intraocular melanoma and one 231 
soft tissue sarcoma  resection (medial thigh).  All dogs recovered uneventfully from surgery. 232 
The first accelerometer was placed a median of 13 days later (range: 7 to 44 days) by which 233 
time, 6/9 dogs had had their sutures removed. 234 
 235 
Over the course of the study, 9 TG dogs (60%) received carboplatin, 3 dogs received 236 
doxorubicin, 1 dog epirubicin and 2 dogs a combination of epirubicin and doxorubicin. 237 
Fifteen dogs had one or more chemotherapy doses, 14 dogs had 3 or more chemotherapy 238 
doses and 6 dogs had 5 or more chemotherapy doses (figure 3). Five dogs (33%) received 239 
concurrent medication throughout the data collection period (meloxicam (3 dogs), 240 
prednisolone (1 dog) and tramadol (1 dog)). One dog received concurrent joint 241 
supplementation throughout the data collection period with a glucosamine and 242 
methylsulfonylmethane combination nutraceutical. The same dog received weekly 243 
hydrotherapy which was performed the day prior to chemotherapy administration which was 244 
not during accelerometer placement. 245 
 246 
Collars were not removed overnight, however some owners did remove accelerometers for 247 
short periods of time and results were adjusted to account for this.  Specifically there were 8 248 
problems (out of 49 accelerometer placements) recorded by owners in the activity diaries. 249 
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These resulted in exclusion of the whole accelerometer episode from analysis in one case, an 250 
exclusion of one day of data in one case and no action in six cases. 251 
 252 
Physical activity measured over 5 days in the CG 253 
The median of the mean 5-day volume of PA for all 15 dogs in the CG was 482 cpm (IQR: 254 
275). A median of the mean of 1268 minutes/day (21.1 hours/day) (IQR: 88 minutes/day) 255 
was spent in sedentary behaviour, 154 minutes/day (2.6 hours/day) (IQR: 76 minutes/day) in 256 
light-moderate activity and 6 minutes/day (0.1 hours/day) (IQR: 10 minutes/day) in vigorous 257 
activity.  258 
 259 
Physical activity measured over 5 days at different accelerometer placement time points 260 
for TG dogs versus CG dogs 261 
Figure 4 shows box and whisker plots for the mean 5-day volume of PA (cpm) at each 262 
accelerometer time point for the TG dogs and their paired CG dogs. Table 2 shows the 263 
median of the mean daily time spent at each intensity of PA (minutes/day).  264 
Changes in PA in TG dogs measured over 5 days at different accelerometer placement 265 
time points 266 
Figure 5 is a box and whisker plot of the median change in mean 5-day volume of PA (cpm) 267 
for TG dogs between the different accelerometer placement time points. Table 3 shows the 268 
differences between the mean daily time spent at each intensity of PA for TG dogs at 269 
different accelerometer placement time points.  270 
 271 
Daily PA in TG dogs on each of the 5 days following chemotherapy 272 
Figure 6 shows the median of the mean daily volume of PA (cpm) for the TG dogs on each of 273 
the 5 days following chemotherapy for doses 1, 3 and 5. Table 4 shows the median time spent 274 
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at different activity intensity levels (minutes/day) for the TG dogs on each of the 5 days 275 
following chemotherapy for doses 1, 3 and 5.  276 
 277 
Discussion   278 
The aim of this study was to objectively measure PA in dogs before, during and after 279 
receiving chemotherapy as an objective measure of QOL. This was successfully achieved in 280 
15/17 dogs that fulfilled the inclusion criteria.  281 
 282 
Prior to chemotherapy, TG dogs had a slightly lower mean 5-day volume of PA (figure 4A) 283 
and tended to spend more time sedentary and slightly less time in light-moderate intensity 284 
activity (table 2), compared to the CG dogs. This may have occurred as TG dogs were not 285 
healthy and were either presumed to have  micrometastatic disease (gross metastases were 286 
ruled out on initial staging) or had gross disease (one case only), both of which could have 287 
affected their PA. Additionally, 8/9 TG dogs had had tumour resection surgery a median of 288 
13 days before accelerometer placement and either the surgery itself or post-surgical exercise 289 
restriction (“lead walks” only until suture removal) could have affected their PA. To reduce 290 
the effect of surgery on PA, post-operative accelerometer placement was delayed for as long 291 
as possible; however given that the optimal time for chemotherapy administration is when 292 
there is minimal residual disease, the time between surgery and the first dose of 293 
chemotherapy is often short. Surgery is likely to have had the greatest effect on the 3 dogs in 294 
this group that had had limb surgery and the effect of post-surgical exercise restriction was 295 
only likely to be relevant in the 3 patients that had accelerometers placed before suture 296 
removal.  297 
 298 
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When the activity of the TG dogs at restage was compared to the CG dogs, no obvious 299 
differences in PA were seen (figure 4E, table 2). Furthermore, when the PA of TG dogs 300 
before chemotherapy was compared to that at restaging, a slight increase in total volume of 301 
PA was seen (figure 5) with a slight reduction in sedentary behaviour and increase in light-302 
moderate intensity activity (table 3). These findings suggest that some factor was reducing 303 
PA in the TG dogs before chemotherapy, however these effects were only very small and a 304 
large variation was seen between TG and CG dogs. 305 
 306 
The effect of chemotherapy on PA in our patients was not marked. Slightly lower mean 5-day 307 
volumes of PA (figure B-D) and greater amounts of time spent sedentary rather than in light-308 
moderate intensity activity (table 2) were seen in TG dogs after all chemotherapy doses when 309 
compared to CG dogs, but there was considerable overlap. Conversely, when TG dogs were 310 
compared to themselves, there was a slight increase in the mean 5-day volume of PA from 311 
before chemotherapy to after chemotherapy doses 1 and 3 (but not 5) (figure 5). This effect 312 
was quite marked in some dogs. Likewise, there was a slight decrease in the amount of time 313 
spent sedentary and a corresponding increase in the time spent in light-moderate intensity 314 
activity from before chemotherapy to after doses 1 and 3 (table 3). The opposite was seen 315 
after dose 5. The apparent contradiction between the results when TG dogs were compared to 316 
CG dogs and when TG dogs were compared to themselves may be because of ongoing effects 317 
of the tumour itself or of surgery which would affect the former but not the latter. 318 
 319 
Similarly, little effect of chemotherapy on PA was seen in the 5 days immediately after 320 
treatment (figure 6, table 4). If anything, there was a slight reduction in the time spent 321 
sedentary and corresponding increase in time spent at light-moderate intensity activity on day 322 
3 post-chemotherapy.  323 
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When the PA of TG dogs was compared during chemotherapy to the restage time point 325 
(figure 5,   table 3), the mean 5-day volume of PA was relatively unchanged and only a very 326 
mild decline in time spent sedentary and increase in time spent in light-moderate intensity 327 
activity was seen. This either suggests that the chemotherapy was not having a major effect 328 
on PA or that the negative effects of chemotherapy are offset by the negative effects of the 329 
residual tumour at the restage time point.  330 
 331 
The relative lack of an effect of chemotherapy on PA is somewhat at odds with the 332 
information in both the human and veterinary literature. In people,  fatigue is one of the most 333 
commonly reported symptoms during palliative and adjuvant chemotherapy (Skerman and 334 
others 2011, Backman and others 2014), however it is a subjective feeling and may not 335 
necessarily translate into a decline in PA. In the only two studies using accelerometry to 336 
measure PA in people on chemotherapy (Tan and others 2013, Vermaete and others 2014), a 337 
reduction in PA was seen. These were, however, studies of patients treated with multi-agent, 338 
curative-intent protocols for acute leukaemias and lymphomas which may be more likely to 339 
have negative effects on PA than the palliative/adjuvant single-agent protocols used in this 340 
study.  341 
 342 
In dogs, chemotherapy has frequently been reported to cause lethargy (Lucroy and others 343 
1998, Mellanby and others 2003, Bowles and others 2010, Marrington and others 2012, 344 
Rivera and others 2013), however these studies all rely on owner reporting, in some cases 345 
months after the treatment took place (Mellanby and others 2003, Bowles and others 2010). 346 
This methodology may introduce bias as some owners may expect their dogs to be lethargic 347 
because of preconceptions about chemotherapy or they may under or overestimate their pet’s 348 
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activity levels due to difficulties recalling and reporting this type of information accurately 349 
(Durante and Ainsworth 1996, Kriska and others 1997, Sirard and Pate 2001). This study, by 350 
contrast, used an objective measure of PA which eliminates many of these problems.   351 
 352 
It is a concern that if the effects of chemotherapy on PA (and therefore QOL) are over-353 
exaggerated this could lead to the misinformation of owners. As the risk of reducing QOL is 354 
often cited by owners as a reason for electing euthanasia rather than treatment (Slater and 355 
others 1996) this could incorrectly deter owners from electing to treat their pets. It should be 356 
remembered, however that the numbers in this study are small and therefore effects on PA 357 
could have been missed. Additionally, QOL is multifactorial and only one aspect was studied, 358 
therefore comments cannot be made on QOL as a whole. 359 
 360 
It was not possible, in this study, to perform meaningful statistical analyses due to the small 361 
sample size. Post-hoc power calculations were performed which suggested large numbers of 362 
dogs would be needed in each group to detect a meaningful difference in PA. This suggests 363 
future studies would need to involve multiple centres and a longer period of data collection. 364 
The power of this study was further reduced because we did not succeed in placing 365 
accelerometers on all TG dogs at all time points (particularly the pre-chemotherapy time 366 
point).   367 
 368 
This preliminary study showed that it was possible to use accelerometers in clinical patients 369 
receiving chemotherapy to collect objective, contemporaneous data on PA. This methodology 370 
could therefore be used in future studies looking at the QOL of patients on chemotherapy 371 
possibly in combination with questionnaires. In this setting, it might also be interesting to 372 
compare results to a control group of patients in which treatment was declined. This would 373 
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provide information on the effect of surgery and the tumour itself, variables which could not 374 
be isolated in this study. Combining accelerometry with other methods of assessing QOL 375 
would also allow relationships between these methods to be investigated. The routine use of 376 
accelerometers in outcome studies of veterinary patients receiving palliative and adjuvant 377 
chemotherapy protocols, where it is suggested that measuring QOL is particularly important 378 
(Spitzer and others 1981, Gunnars and others 2001, Sprangers 2002), should be considered. 379 
The inclusion of more homogeneous groups of patients (with regards to tumour type and drug 380 
administered) would allow additional conclusions to be drawn. Objective measurement of PA 381 
may be particularly relevant in studies of drugs like the tyrosine kinase inhibitors which are 382 
known to have a direct effect on the musculoskeletal system (London and others, 2009). As 383 
accelerometry was well tolerated and contemporaneous, it could also be used in individual 384 
clinical patients to provide objective information on patient QOL that could help owners and 385 
clinicians decide whether to make changes or discontinue a protocol. 386 
 387 
In conclusion, we have shown that the concept of measuring PA using accelerometry in 388 
canine oncological patients is valid and our results support the use of single-agent adjuvant 389 
chemotherapy in dogs given that marked changes in PA were not seen during treatment. 390 
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FIGURE LEGENDS 557 
Figure 1: Dog wearing ActiGraph™ accelerometer attached to collar. 558 
 559 
Figure 2: Counts recorded for each minute of a 24 hour day for a dog wearing an 560 
accelerometer. The y-axis is divided into sections to show the cut points for the different 561 
physical activity intensity levels. PA = physical activity. 562 
 563 
Figure 3: Flow diagram demonstrating TG dogs throughout the study (number of dogs, 564 
number of dogs with accelerometers fitted). a 8 of these dogs had surgery prior to 565 
accelerometer placement (median time from surgery to accelerometer placement was 13 566 
days), b the median time to restage for all dogs was 33 days.  567 
 568 
Figure 4: Box and whisker plots for the mean 5-day volume of physical activity (counts per 569 
minute [cpm]) at each accelerometer time point for the treatment group dogs and their paired 570 
control dogs. The n-value is the number of dogs in each group. The lower and upper 571 
boundaries of the box represent the first and third quartiles of the data respectively and the 572 
line within the box represents the median. The whiskers represent the complete range of the 573 
data. Outliers (*) are observations that are at least 1.5 times the interquartile range from the 574 
edge of the box. 575 
 576 
 21 
Figure 5: Box and whisker plot of the change in mean 5-day volume of physical activity 577 
(counts per minute [cpm]) for treatment group dogs between the different time points listed 578 
on the y-axis. Values below zero represent an increase in the mean 5-day volume of physical 579 
activity whereas values above the line represent a decrease in the mean 5-day volume of 580 
physical activity. Dogs were only included in each group if data was available from both time 581 
points. Pre = pre-chemotherapy, C1 = after 1st chemotherapy, C3 = after 3rd chemotherapy, 582 
C5 = after 5th chemotherapy. The n-value is the number of dogs in each group. The lower and 583 
upper boundaries of the box represent the first and third quartiles of the data respectively and 584 
the line within the box represents the median. The whiskers represent the complete range of 585 
the data. Outliers (*) are observations that are at least 1.5 times the interquartile range from 586 
the edge of the box. 587 
 588 
Figure 6: Box and whisker plots of the mean daily volume of physical activity (counts per 589 
minute [cpm]) for the treatment group dogs on each of the 5 days following chemotherapy 590 
doses 1, 3 and 5. The n-value is the number of dogs in each group. *Only dogs with all 5 days 591 
of data were included. The lower and upper boundaries of the box represent the first and third 592 
quartiles of the data respectively and the line within the box represents the median. 593 
 594 
TABLE LEGENDS 595 
Table 1: Descriptive characteristics of the dogs in the treatment and control groups.  596 
 597 
Table 2: Mean daily time spent at each intensity of physical activity (minutes per day) at each 598 
accelerometer time point for the treatment group dogs and their paired control dogs. 599 
 600 
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Table 3: Difference between the mean daily time spent at each intensity of physical activity 601 
by the treatment group dogs at different accelerometer time points. 602 
 603 
Table 4: Time spent at different activity intensity levels (minutes per day) for the treatment 604 
group dogs on each of the 5 days following chemotherapy doses 1, 3 and 5.  605 
 606 
